Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 5,921 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Completed Phase 2 Interventional

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

NCT00002314
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Ro 24-7429
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis

NCT01156155
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis, Periodontal Disease
Interventions
Digital xray of jaw and teeth, Blood draw, questionnaires, Periodontal Examination, Bilateral digital xray of hands
Radiation · Procedure · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
617 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 31, 2026, 8:15 PM EDT
Not yet recruiting Not applicable Interventional

A Clinical Trial of the Administration of Light Therapy to Prevent Mouth Sores in Children With Cancer

NCT06623305
View directory record Official record
Conditions
Mucositis Oral
Interventions
Photobiomodulation for prevention arm, Photobiomodulation for exploratory arm
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

BIO 300 Non-Small Cell Lung Cancer Study

NCT02567799
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIO 300 Oral Suspension, Paclitaxel, Carboplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

NCT01185821
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BAF312
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 56 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
8
States / cities
Miami, Florida • Pompano Beach, Florida • Tallahassee, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 31, 2026, 8:15 PM EDT
Recruiting Phase 1 Interventional

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06896916
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Iberdomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
7
States / cities
Beverly Hills, California • Denver, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

NCT04566601
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Anaheim, California • Temecula, California • Upland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 31, 2026, 8:15 PM EDT
Completed No phase listed Observational

Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms

NCT04192916
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
DOACs
Drug
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Other
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

NCT05333107
View directory record Official record
Conditions
Healthy Volunteers; High Cholesterol
Interventions
NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Cypress, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 31, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

NCT01403064
View directory record Official record
Conditions
Oral Mucositis
Interventions
ALD518, 0.9% saline
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 31, 2026, 8:15 PM EDT
Recruiting Phase 2 Interventional

Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA

NCT07828704
View directory record Official record
Conditions
Kidney Cancers
Interventions
5-Aminolevulinic acid Hydrochloride (Gliolan®)
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

NCT07233239
View directory record Official record
Conditions
Focal Seizures
Interventions
CBD-OS
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Beverly Hills, California • Lake Forest, California • Santa Maria, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Workflow Validation of an In-home Auto-titrating Mandibular Positioner

NCT02933112
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Auto-titrating mandibular positioner test
Device
Lead sponsor
Zephyr Sleep Technologies
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

NCT01744730
View directory record Official record
Conditions
Bacterial Infections, Obesity
Interventions
Clindamycin
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

NCT02958865
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
60
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer

NCT00094081
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
tirapazamine (SR259075), cisplatin, Radiation Therapy
Drug · Procedure
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
10
States / cities
Phoenix, Arizona • Palo Alto, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

NCT00477971
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, dexamethasone, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 31, 2026, 8:15 PM EDT
Recruiting Phase 1 Interventional

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

NCT07012044
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

NCT05625334
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASA, non-enteric-coated chewable aspirin
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML

NCT00780598
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML
Interventions
Tosedostat
Drug
Lead sponsor
Chroma Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 31, 2026, 8:15 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to Sitagliptin (PRS)

NCT06813014
View directory record Official record
Conditions
Diabetes
Interventions
Oral Glucose Tolerance Test
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

NCT00974311
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 31, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional Results available

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
View directory record Official record
Conditions
Hen Egg Allergy
Interventions
AR201 powder, Placebo powder
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 31, 2026, 8:15 PM EDT